Search results for "Alcoholic"

showing 10 items of 509 documents

Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nona…

2017

Abstract Aims: Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, panlobular inflammation, liver fibrosis, and increased cardiovascular mortality. Dipeptidyl peptidase-4 inhibitors (gliptins) are indirect glucagon-like peptide 1 agonists with antidiabetic and anti-inflammatory activity, used for the treatment of type 2 diabetes. Their potential and underlying mechanisms to treat metabolic liver inflammation and fibrosis as well as the associated vascular dysfunction remain to be explored. Results: In the methionine/choline-deficient (MCD) diet and Mdr2−/− models of NASH and liver fibrosis, treatment with sitagliptin and linagliptin significantly decreased parameters of steat…

0301 basic medicinemedicine.medical_specialtyPhysiologyClinical BiochemistryAnti-Inflammatory AgentsGene ExpressionInflammationType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryAntioxidantsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicinemedicineAnimalsMyeloid CellsMolecular BiologyDipeptidyl peptidase-4General Environmental ScienceInflammationMice KnockoutDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMacrophagesCell BiologyMacrophage Activationmedicine.diseaseFibrosisDietDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyLiverNADPH Oxidase 2General Earth and Planetary SciencesTumor necrosis factor alphaSteatosismedicine.symptomReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants & Redox Signaling
researchProduct

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nona…

2018

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the …

0301 basic medicinemedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulation03 medical and health sciencesLiver disease0302 clinical medicineLipid oxidationFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineeducationNASH NAFLDeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryOriginal ArticlesHepatologymedicine.diseasen/a030104 developmental biologyEndocrinologyLiver biopsy030211 gastroenterology & hepatologyOriginal ArticleSteatosisbusiness
researchProduct

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

2019

Background & Aims: Non-alcoholic fatty liver disease and alcohol-related liver disease pose an important challenge to current clinical healthcare pathways because of the large number of at-risk patients. Therefore, we aimed to explore the cost-effectiveness of transient elastography (TE) as a screening method to detect liver fibrosis in a primary care pathway. Methods: Cost-effectiveness analysis was performed using real-life individual patient data from 6 independent prospective cohorts (5 from Europe and 1 from Asia). A diagnostic algorithm with conditional inference trees was developed to explore the relationships between liver stiffness, socio-demographics, comorbidities, and hepati…

0301 basic medicinemedicine.medical_specialtyTransient elastographyPopulationLiver fibrosisDisease03 medical and health sciencesLiver disease0302 clinical medicineFibrosisInternal medicinemedicineeducationeducation.field_of_studyAlcohol-related liver diseaseHepatologybusiness.industryFatty liverCost-effectiveness analysismedicine.disease3. Good health030104 developmental biologyStratified screening030211 gastroenterology & hepatologyTransient elastographybusinessHepatic fibrosisNon-alcoholic fatty liver disease
researchProduct

Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches

2021

Current treatment recommendations for non-alcoholic fatty liver disease (NAFLD) rely heavily on lifestyle interventions. The Mediterranean diet and physical activity, aiming at weight loss, have shown good results in achieving an improvement of this liver disease. However, concerns related to compliance and food accessibility limit the feasibility of this approach, and data on the long-term effects on liver-related outcomes are lacking. Insulin resistance is a central aspect in the pathophysiology of NAFLD; therefore, interventions aiming at the improvement of insulin sensitivity may be preferable. In this literature review, we provide a comprehensive summary of the available evidence on nu…

0301 basic medicinemedicine.medical_specialtyinsulinlifestyletime-restricted feedingsteatohepatitisDiseaseReviewmetabolic syndrome03 medical and health sciencesLiver disease0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseWeight lossIntermittent fastingmedicineTime‐restricted feedingHumansTX341-641Intensive care medicineLife StyleNutrition and DieteticsNon‐alcoholicbusiness.industryNutrition. Foods and food supplyintermittent fastinglow-carb dietFatty liverfibrosismedicine.diseaseDietGastrointestinal MicrobiomeLow‐carb diet030104 developmental biologynon-alcoholicFibrosis; Insulin; Intermittent fasting; Lifestyle; Liver disease; Low‐carb diet; Metabolic syndrome; Non‐alcoholic; Steatohepatitis; Time‐restricted feeding; Weight loss030211 gastroenterology & hepatologyInsulin ResistanceSteatohepatitismedicine.symptomMetabolic syndromeweight lossbusinessliver diseaseFood ScienceNutrients
researchProduct

Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.

2019

Background & Aims Nonalcoholic steatohepatitis causes loss of hepatic CD4+ T cells and promotes tumor growth. The liver is the most common site of distant metastases from a variety of malignancies, many of which respond to immunotherapy. We investigated the effects of steatohepatitis on the efficacy of immunotherapeutic agents against liver tumors in mice. Methods Steatohepatitis was induced by feeding C57BL/6NCrl or BALB/c AnNCr mice a methionine and choline–deficient diet or a choline-deficient l-amino acid–defined diet. Mice were given intrahepatic or subcutaneous injections of B16 melanoma and CT26 colon cancer cells, followed by intravenous injections of M30-RNA vaccine (M30) or intrap…

0301 basic medicinemedicine.medical_treatmentT cellT-LymphocytesArticleMetastasis03 medical and health sciencesMice0302 clinical medicineImmune systemNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineAnimalsMelanomaTumor microenvironmentMice Inbred BALB CHepatologybiologybusiness.industryLiver NeoplasmsGastroenterologyImmunotherapymedicine.diseaseMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structurebiology.proteinCancer research030211 gastroenterology & hepatologyImmunotherapySteatohepatitisAntibodybusinessGastroenterology
researchProduct

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

2019

Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease …

0301 basic medicinenonalcoholic fatty liver diseasemedicine.medical_specialtyDyslipidemias; Genetics; Inflammation; Liver; Triglycerides; genes in lipid dysfunction; metabolic disease; non-alcoholic fatty liver diseaseHyperlipidemiasInflammationQD415-436030204 cardiovascular system & hematologyBiochemistryproprotein convertase subtilisin/kexin type 703 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyGeneticInternal medicineNonalcoholic fatty liver diseasemedicineGeneticsHumansSubtilisinsAlleleTriglyceridesDyslipidemiasHypertriglyceridemiaInflammationgenes in lipid dysfunctionmedicine.diagnostic_testbusiness.industrynon-alcoholic fatty liver diseaseCell Biologymedicine.diseasemetabolic disease030104 developmental biologyEndocrinologyLiverLiver biopsyLipogenesisKexinmedicine.symptomPatient-Oriented and Epidemiological ResearchbusinessDyslipidemia
researchProduct

Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling

2020

The farnesoid X receptor (FXR) plays a critical role in the regulation of lipid and bile acid (BA) homeostasis. Hepatic FXR loss results in lipid and BA accumulation, and progression from hepatic steatosis to nonalcoholic steatohepatitis (NASH). This study aimed to evaluate the effects of xanthohumol (XN), a hop-derived compound mitigating metabolic syndrome, on liver damage induced by diet and FXR deficiency in mice. Wild-type (WT) and liver-specific FXR-null mice (FXRLiver−/−) were fed a high-fat diet (HFD) containing XN or the vehicle formation followed by histological characterization, lipid, BA and gene profiling. HFD supplemented with XN resulted in amelioration of hepatic steatosis a…

0301 basic medicinenonalcoholic fatty liver diseasemedicine.medical_specialtymedicine.drug_classRM1-95003 medical and health scienceschemistry.chemical_compound0302 clinical medicineGlucocorticoid receptorInternal medicineConstitutive androstane receptorlipid metabolismmedicinePharmacology (medical)Original ResearchPharmacologybile acidsPregnane X receptorBile acidChemistryLipid metabolismmedicine.diseasexanthohumol030104 developmental biologyEndocrinologyXanthohumol030211 gastroenterology & hepatologyFarnesoid X receptorTherapeutics. PharmacologySteatosisfarnesoid X receptorFrontiers in Pharmacology
researchProduct

Genomic and non-genomic mechanisms of action of thyroid hormones and their catabolite 3,5-diiodo-l-thyronine in Mammals

2020

Since the realization that the cellular homologs of a gene found in the retrovirus that contributes to erythroblastosis in birds (v-erbA), i.e. the proto-oncogene c-erbA encodes the nuclear receptors for thyroid hormones (THs), most of the interest for THs focalized on their ability to control gene transcription. It was found, indeed, that, by regulating gene expression in many tissues, these hormones could mediate critical events both in development and in adult organisms. Among their effects, much attention was given to their ability to increase energy expenditure, and they were early proposed as anti-obesity drugs. However, their clinical use has been strongly challenged by the concomita…

0301 basic medicinenonalcoholic fatty liver diseaseobesityDiiodothyroninesEndogenyReviewthyroid hormone metabolism and transportMitochondrionmedicine.disease_causeProto-Oncogene Maslcsh:Chemistry0302 clinical medicineTranscription (biology)Settore BIO/10 - BiochimicaGene expressionSettore BIO/06 - Anatomia Comparata E CitologiaSettore MED/49 - Scienze Tecniche Dietetiche Applicatelcsh:QH301-705.5SpectroscopyMammalsReceptors Thyroid Hormonehepatic steatosisthyroid hormone mechanisms of actionGeneral Medicineresistance to thyroid hormones (RTH)Computer Science ApplicationsCell biology35-diiodo-L-thyronineThyroid Hormones030209 endocrinology & metabolismBiologyIodide PeroxidaseCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyGeneOrganic ChemistryBiological TransportLipid Metabolismhepatic steatosi030104 developmental biologyNuclear receptorlcsh:Biology (General)lcsh:QD1-999MutationBasal MetabolismLipid PeroxidationOxidative stressHormone
researchProduct

Inoculation of Torulaspora delbrueckii as a bio-protection agent in winemaking

2018

International audience; In oenology, bio-protection consists in adding bacteria, yeasts or a mixture of microorganisms on grape must before fermentation in order to reduce the use of chemical compounds such as sulphites. More particularly, non-Saccharvinyces yeasts are used as a total or partial alternative to sulphites. However, scientific data capable of proving the effectiveness of adding these yeasts on grape must is lacking. This study reports the analysis of antimicrobial and antioxidant effects of one non-Saccharamyces yeast, Torulaspora delbruecicii, inoculated at the beginning of the white winemaldng process in two Burgundian wineries as an alternative to sulphiting. The implantati…

0301 basic medicinesulfur-dioxideMicroorganism030106 microbiologyTorulaspora delbrueckiiwhite winesWinechardonnay winesAntioxidants03 medical and health sciencesTorulaspora delbrueckiialcoholic fermentationOxidation[SDV.IDA]Life Sciences [q-bio]/Food engineeringVitisFood sciencecerevisiaeOenologyWinemakingWinebiologyChemistrysequential inoculationfood and beveragesTorulasporaWine bio-protectionribosomal-rna genenon-saccharomyces yeastsbiology.organism_classificationAntimicrobialYeastwine fermentationNon-Saccharomyces yeastFermentationFood MicrobiologyFermentationmixed culturesAlternative to sulphitesFood ScienceFood Research International
researchProduct

<i>NR1H4</i> rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease

2020

Background and Aims: Farnesoid X receptor (FXR) plays a key role in bile acid and lipid homeostasis. Experimental evidence suggests that it can modulate liver damage related to nonalcoholic fatty liver disease (NAFLD). We examined the impact of the NR1H4 rs35724 variant, encoding for FXR, on liver damage in a large cohort of patients at risk of steatohepatitis. Methods: We considered 2,660 consecutive individuals at risk of steatohepatitis with liver histology. The rs35724 G>C polymorphisms was genotyped by TaqMan assays. Gene expression was evaluated by RNASeq in a subset of patients (n=124). Results: The NR1H4 rs35724 variant was protective against severity of steatosis (OR 0.89, 95% C.I.…

0303 health sciencesmedicine.medical_specialtyBile acidCholesterolbusiness.industrymedicine.drug_class030302 biochemistry & molecular biologymedicine.diseaseGastroenterology3. Good health03 medical and health scienceschemistry.chemical_compoundchemistryFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineCYP39A1Farnesoid X receptorSteatosisSteatohepatitisbusiness030304 developmental biologySSRN Electronic Journal
researchProduct